Mari Nakazawa

Mari Nakazawa

Auto-generated profile, based on publicly available information

Mari Nakazawa

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, a member of the imCORE network, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
CLChangxue Lu
Changxue Lu
HWHao Wang
Hao Wang
BLBrandon Luber
Brandon Luber
MNMary Nakazawa
Mary Nakazawa
JLJun Luo
Jun Luo
The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection of androgen-receptor splice variant 7 messenger RNA (AR-V7) in circulating tumor cells from men with advanced prostate cancer would be associated with resistance to enzalutamide and abiraterone. We used a quantitative reverse-transcriptase–polymerase-chain-reaction assay to evaluate AR-V7 in circulating tumor cells from prospectively enrolled patients with metastatic castration-resistant prostate cancer who were initiating treatment with either enzalutamide or abiraterone. We examined associations between AR-V7 status (positive vs. negative) and prostate-specific antigen (PSA) response rates (the primary end point), freedom from PSA progression (PSA progression–free survival), clinical or radiographic progression–free survival, and overall survival. A total of 31 enzalutamide-treated patients and 31 abiraterone-treated patients were enrolled, of whom 39% and 19%, respectively, had detectable AR-V7 in circulating tumor cells. Among men receiving enzalutamide, AR-V7–positive patients had lower PSA response rates than AR-V7–negative patients (0% vs. 53%, P=0.004) and shorter PSA progression–free survival (median, 1.4 months vs. 6.0 months; P<0.001), clinical or radiographic progression–free survival (median, 2.1 months vs. 6.1 months; P<0.001), and overall survival (median, 5.5 months vs. not reached; P=0.002). Similarly, among men receiving abiraterone, AR-V7–positive patients had lower PSA response rates than AR-V7–negative patients (0% vs. 68%, P=0.004) and shorter PSA progression–free survival (median, 1.3 months vs. not reached; P<0.001), clinical or radiographic progression–free survival (median, 2.3 months vs. not reached; P<0.001), and overall survival (median, 10.6 months vs. not reached, P=0.006). The association between AR-V7 detection and therapeutic resistance was maintained after adjustment for expression of full-length androgen receptor messenger RNA. Detection of AR-V7 in circulating tumor cells from patients with castration-resistant prostate cancer may be associated with resistance to enzalutamide and abiraterone. These findings require large-scale prospective validation. (Funded by the Prostate Cancer Foundation and others.)

1 August 2015 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
CLChangxue Lu
Changxue Lu
BLBrandon Luber
Brandon Luber
HWHao Wang
Hao Wang
YCYan Chen
Yan Chen
JLJun Luo
Jun Luo
There are currently 6 available therapies for the treatment of castration-resistant prostate cancer (CRPC), all of which have produced survival improvements.1 These therapies fall into 4 classes: androgen receptor (AR)-directed therapies (abiraterone acetate,2 enzalutamide3), taxane chemotherapies (docetaxel,4 cabazitaxel5), immunotherapies (sipuleucel-T6), and bone-targeting radiopharmaceuticals (radium-223).7 Of these, the most widely used are the AR-targeting therapies and the chemotherapies. However, mechanisms of response and resistance to these therapies remain poorly understood.8,9 Furthermore, predictive biomarkers aiding in treatment selection (ie, selecting for or against a particular therapy) are still lacking, although prognostic markers are abundant.10

27 June 2015 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
MNM. Nakazawa
M. Nakazawa
CLC. Lu
C. Lu
YCY. Chen
Y. Chen
CPC. J. Paller
C. J. Paller
MCM. A. Carducci
M. A. Carducci
EAE. S. Antonarakis
E. S. Antonarakis
We previously showed that pretreatment detection of androgen receptor splice variant-7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer is associated with resistance to abiraterone and enzalutamide, but not to taxane chemotherapies. Here, we conducted serial measurements of AR-V7 and evaluated patterns of longitudinal AR-V7 dynamics over the course of multiple sequential therapies. Metastatic prostate cancer patients treated at Johns Hopkins with AR-directed therapies or taxane chemotherapies underwent serial liquid biopsies for CTC-based AR-V7 analysis at baseline, during therapy, and at progression. We used a CTC enrichment platform followed by multiplexed reverse-transcription polymerase chain reaction analysis to detect full-length androgen receptor and AR-V7 transcripts. Patients selected for inclusion in this report were those who provided ≥4 CTC samples, at least one of which was AR-V7 positive, over the course of ≥2 consecutive therapies. We identified 14 patients who received a total of 37 therapies and contributed 70 CTC samples for AR-V7 analysis during a median follow-up period of 11 months. Three patients remained AR-V7 positive during the entire course of therapy. The remainder underwent transitions in AR-V7 status: there were eight instances of ‘conversions’ from AR-V7-negative to -positive status (during treatment with first-line androgen deprivation therapy, abiraterone, enzalutamide, and docetaxel), and six instances of ‘reversions’ from AR-V7-positive to -negative status (during treatment with docetaxel and cabazitaxel). AR-V7 is a dynamic marker, and transitions in AR-V7 status may reflect selective pressures on the tumor exerted by therapeutic interventions. While ‘conversions’ to AR-V7-positive status were observed with both AR-directed therapies and taxane chemotherapies, ‘reversions’ to AR-V7-negative status only occurred during taxane therapies. Serial blood-based AR-V7 testing is feasible in routine clinical practice, and may provide insights into temporal changes in tumor evolution.

22 February 2017 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
MNMary Nakazawa
Mary Nakazawa
CPChanning Paller
Channing Paller
Natasha KyprianouNatasha Kyprianou
Natasha Kyprianou

22 July 2014 in Discover Oncology
Verified
Journal Article
Closed access
PDF file
MNMary Nakazawa
Mary Nakazawa
EAEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
JLJun Luo
Jun Luo

21 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CKChester Kao
Chester Kao
SCSoren Charmsaz
Soren Charmsaz
HTHua-Ling Tsai
Hua-Ling Tsai
KAKhaled Aziz
Khaled Aziz
DSDaniel H. Shu
Daniel H. Shu
DZDaniel J. Zabransky
Daniel J. Zabransky
Most new cancer diagnoses occur in patients over the age of 65. The composition and function of the immune system changes with age, but how the aged immune system affects responses to immune checkpoint inhibitor (ICI) cancer therapies remains incompletely understood. Here, using multiplex cytokine assay and high-parameter mass cytometry, we analyze prospectively collected blood samples from 104 cancer patients receiving ICIs. We find aged patients ( ≥ 65-years-old; n = 54) derive similar clinical outcomes as younger patients (n = 50). However, aged, compared to young, patients have divergent immune phenotypes at baseline that persist during ICI therapy, including diminished cytokine responses, reduced pools of naïve T cells with increased relative expression of immune checkpoint molecules, and more robust effector T cell expansion in responders compared to non-responders. Our study provides insights into age-stratified mechanisms of ICI effects while also implying the utility of age-tailored immunotherapeutic approaches.